Brought to you by 
BI licenses exclusive rights to Hanmi's HM61713 lung cancer candidate; later gives back rights
06 Oct 2016
Executive Summary
Boehringer Ingelheim GMBH licensed exclusive worldwide rights (except in South Korea, China, and Hong Kong) to South Korean firm Hanmi Pharmaceutical Co. Ltd.'s HM61713, a third-generation candidate for epidermal growth factor receptor (EGFR) mutation-positive lung cancer.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
-
Drug Discovery Tools
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com